The effects of melatonin on glucose and lipids profile in type II diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012062610115N1

Enrollment

Registered

2012-07-06

Start date

2012-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus type2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: intervention: tab melatonin 3mg, 2 tab /day for 12 weeks. Intervention 2: control: placebo, 2 tab/day for 12 weeks.

Treatment - Drugs

Placebo

intervention: tab melatonin 3mg, 2 tab /day for 12 weeks

control: placebo, 2 tab/day for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: diabetes mellitus type II; serum Cr <2 mg/dl; HbA1c <8.5%. Exclusion criteria: melatonin consumption; pregnancy or breast feeding; current or history of epilepsy; smoking; drug addiction; alcohol or amphetamine abuse; warfarin or nifidipin medication; shifting job; history of coagulopathy or bleeding; change in diabetic or anti lipid treatment protocol; starting treatment by beta-blockers or diuretics.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting Blood Suger. Timepoint: weeks 0,12,24. Method of measurement: laboratory.;Lipid profile. Timepoint: weeks 0,12,24. Method of measurement: laboratory.;HbA1c (%). Timepoint: weeks 0,12,24. Method of measurement: laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Glare Heshmati

Arak university of medical sciences

dr.heshmati@arakMM.ac.ir+98 86 1223 5605

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026